StockData
Janux Therapeutics, Inc. logo

Janux Therapeutics, Inc. (JANX) stock

JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3037% below fair value
$10.71−0.21 (-1.92%)

Close on Nov 17, 2026Market cap $654.78MP/E –Yield –

Earnings

Janux Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 25, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$9.29M
EPS, Q3 FY2026
-$0.34
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Janux Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 25, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026after the close$9.29M–-$0.34Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026during market hours–––Release
Q1 FY2026ended Mar 31, 2026May 7, 2026during market hours–––Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026during market hours–––Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025during market hours–––Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025during market hours––-$0.55Release
Q1 FY2025ended Mar 31, 2025May 8, 2025during market hours––-$0.38Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025during market hours–––Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024during market hours–––Release
Q2 FY2024ended Jun 30, 2024Aug 7, 2024during market hours$8.90M+741.7%-$0.11Release
Q1 FY2024ended Mar 31, 2024May 8, 2024after the close$1.25M-38.9%-$0.30Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Janux Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Janux Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Janux Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Update
  6. Results
  7. Results
  8. Results
  9. Results
  10. News
  11. News
  12. Update
  13. Update
  14. Results
  15. Results

See a number that looks wrong?